LEXX vs DLXY Comparison

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Delixy Holdings Ltd a holding company. Through its subsidiary, it is principally engaged in the trading of oil-related products, which are broadly categorized into crude oil and oil-based products, including naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. These products are traded across multiple countries in Southeast Asia, East Asia, and the Middle East, and the Group has established a presence in the oil trading markets in these countries. The majority of the Group's revenue is generated from the trading of crude oil. Geographically, it derives maximum revenue from its business in East Asia.